Skip to main content
. 2018 Sep 20;9(10):957. doi: 10.1038/s41419-018-0974-2

Fig. 2. CPEB1 is downregulated in liver cancer tissue.

Fig. 2

a–d CPEB1 levels, detected by quantitative RT-PCR and immunoblotting, were significantly downregulated in data from The Cancer Genome Atlas (TCGA) and human HCC patient samples (T: tumor tissues, N: adjacent non-tumor tissues). e Immunohistochemical staining of CPEB1 in liver cancer (n = 68, odd rows) and adjacent non-cancerous liver tissues (n = 60, even rows) in a tissue microarray (TMA), the staining scores of CPEB1 in liver cancer were lower than those observed in the adjacent normal liver tissues. Immunohistochemistry staining indicated that CPEB1 immunostaining primarily occurred in the cytoplasm of liver cancer tissues cells. f The expression levels of CPEB1 by immunostaining were moderately positive, weakly positive and negative in cancer samples, stronger staining was observed in peritumoral tissues. Left image, original magnification × 10; right image, magnification × 400; the white squares indicate the area shown at higher magnification. g Correlation analysis of CPEB1 expression with CD133 expression in 80 HCC specimens by qRT-PCR analysis in biopsies and immunohistochemistry staining in paraffin-embedded tissue. The data are presented as the means ± SEM. *P < 0.05